Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Full Supreme Court to hear challenge to Judicial Selection Committee law - 2Scientists Just Discovered Japan’s First New Bird Species in Over 40 Years
- 3Amplifying Cash The executives: The Upsides and downsides of Various Ledgers
- 4Ocean side Locations for a Family Excursion
- 5The Best Traditional Music Arrangers in History
- Israeli Chief of Staff declares new border with Gaza Strip
- Creative Tech Contraptions That Will Work on Your Life
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- The 20 Most sultry Style of the Time
- NASA study shows how satellite 'light pollution' hinders space telescopes
- Parents speak out as 4-year-old fights button battery injury in intensive care unit
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
- Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Vote in favor of your Number one method for praising a birthday
